FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

AMT Designation Program Guidance

[ Price : $8.95]

FDA publishes a guidance with recommendations for participating in the agencys Advanced Manufacturing Technologies Designation Pro...

ICH E11A Pediatric Extrapolation Guidance

[ Price : $8.95]

FDA publishes the International Council on Harmonization E11A Pediatric Extrapolation guidance.

ICH Clinical Practice Guide Annex

[ Price : $8.95]

FDA publishes Annex 2 of the International Council on Harmonization Good Clinical Practice guidance.

Brands International Limits, Delays Inspection: FDA

[ Price : $8.95]

FDA warns a Canadian Brands International facility about limiting and delaying an inspection that also identified CGMP violations.

CRL for Zealands SBS Treatment NDA

[ Price : $8.95]

FDA issues a complete response letter for Zealands glepaglutide intended to treat short bowel syndrome.

Quality, Data Issues at Mylan Facility in India

[ Price : $8.95]

FDA warns a Viatris Mylan drug manufacturing facility in Pradesh, India, about CGMP violations involving quality and data issues.

Boxed Warning for Veozah Liver Injury

[ Price : $8.95]

FDA adds a liver injury Boxed Warning to labeling for Astellas menopause hot flash drug Veozah.

Lexicon Dropping Zynquista After CRL

[ Price : $8.95]

Lexicon stops development of its diabetes drug Zynquista that received an FDA complete response letter.

Hologic BioZorb Marker Recall Class 1: FDA

[ Price : $8.95]

FDA says a Hologic 3/2024 recall correction of BioZorb Markers was Class 1.

UCB Minzasolmin Parkinsons Study Misses Endpoints

[ Price : $8.95]

UCB says it is ending the development of minzasolmin, a drug it was working on with Novartis to treat early Parkinsons disease, af...